Apress vs BosPure vs Raw resin · which to choose

Apress (5-Loxin 30% AKBA) canon RCTs · BosPure 60% AKBA premium · avoid raw resin.

Standardized 30% AKBA extract · Sengupta patent

Best for

Ideal use: OA · canon RCTs · clinical default.

Advantages

Canon RCT form (Sengupta 2008, Vishal 2011, Sengupta 2024 meta). HPLC AKBA standardization validated. Improved bioavailability vs raw resin.

Disadvantages

Medium-high cost (~€25-35/month 250 mg/d). Sami-Sabinsa patent mark-up.

60% AKBA extract superior potency

Best for

Ideal use: high anti-inflammatory requirement · severe RA · IBD.

Advantages

Double AKBA concentration · lower capsule dose. Less volume per take. For high anti-inflammatory potency.

Disadvantages

Expensive (~€35-50/month). Fewer canon RCTs (most use 30% Apress). Validate brand.

Powder without AKBA standardization

Best for

Use NOT recommended (limited): tradition/cultural · NOT clinical therapeutic.

Advantages

Affordable. Ayurvedic tradition.

Disadvantages

Variable AKBA 1-5% across batches. Poor bioavailability. Canon RCTs use standardized.

Which form for your goal?

Apress / 5-Loxin (Sami-Sabinsa 30% AKBA)

Ideal use: OA · canon RCTs · clinical default.

BosPure (60% AKBA premium)

Ideal use: high anti-inflammatory requirement · severe RA · IBD.

Crude boswellia resin

Use NOT recommended (limited): tradition/cultural · NOT clinical therapeutic.

Apress (5-Loxin 30% AKBA) canon RCTs · BosPure 60% AKBA premium · avoid raw resin.